Larimar Therapeutics holds 2025 Annual Meeting; all proposals pass

Larimar Therapeutics, Inc.

Thomas E. Hamilton elected Class II director with 46.5M votes for, 4.3M withheld.
Advisory say-on-pay approved: 49.2M for, 1.4M against, 0.2M abstain.
Ratification of PricewaterhouseCoopers as auditor for 2025: 57.7M for, 10.9K against.
No other material proposals; all votes passed.

item 5.07

Larimar Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-070287

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.